Agios Pharmaceuticals Inc

AGIO has transitioned into Stage 3 distribution, with an active Blow-Off Top marking the terminal phase and short-term EMAs now acting as resistance. Price is rejecting at the 9EMA/21EMA zone after a shallow pullback, confirming a medium-term bearish bias. Short-term conditions also favor continued downside as overbought pressures unwind and rallies fail. Therefore, execution focuses on Sell Now on rallies into the 9EMA/21EMA area to participate in the downtrend.

• ↑Q1 2026 revenue surged 138% YoY to $20.7M, driven by Acvesme U.S. launch
• ↑Phase III RISE UP trial showed significant sickle cell disease benefits for mitapivat
• ↓Stock trades at 35.9× price-to-sales, high relative to peers